CMPMedica shutters two journals

Share this article:
CMPMedica ceased publication on two of its titles—Infections in Medicine and AIDS Reader—due to a continuing decline in print advertising sales.

In early July, the company announced “company-wide” layoffs that “touched every department,” according to Amy Erdman, CMPMedica's director of marketing, research and circulation.

Erdman declined to put a number on the layoffs. An article in Folio put the number of layoffs at “nearly 30,” citing a source familiar with the cuts.

Despite the absence of print issues, both titles will continue to “maintain a digital presence,” said Erdman, adding that other areas of the business, including digital advertising, are seeing positive growth.

Erdman said the company does not have any current plans to stop print publication of other CMPMedica titles, which include Psychiatric Times, The Journal of Respiratory Diseases, Physicians Practice, Oncology News International, Headache & Pain, The Journal of Musculoskeletal Medicine and others.

Diane Carpenteri, previously in charge of sales on Infections in Medicine and the AIDS Reader, left the company in February. Brandofino Communications, publisher of Doctor's Digest, hired Carpenteri onto its sales team in July.
CMPMedica is a division of United Business Media, which also owns PR Newswire, TechWeb and other information trade services and distribution channels.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?